Carcinoembryonic antigen-related cell adhesion molecule 1 and tumor

doi:10.3969/j.issn.1673-8640.2014.09.002

Abstract

CLC Number:

R446.62

YANG Changcheng, WANG Wenjuan, GAO Feng. Carcinoembryonic antigen-related cell adhesion molecule 1 and tumor[J]. , 2014, 29(9): 877-883.

[1] Svenberg T. Carcinoembryonic antigen-like substances of human bile. Isolation and partial characterization[J]. Int J Cancer,1976,17(5): 588-596.
[2] Beauchemin N,Draber P,Dveksler G,et al. Redefined nomenclature for members of the carcinoembryonic antigen family[J]. Exp Cell Res, 1999,252(2): 243-249.
[3] Gray-Owen SD,Blumberg RS. CEACAM1: contact-dependent control of immunity[J]. Nat Rev Immunol,2006,6(6): 433-446.
[4] Skubitz KM,Skubitz AP. Two new synthetic peptides from the N-domain of CEACAM1 (CD66a) stimulate neutrophil adhesion to endothelial cells[J]. Biopolymers,2011,96(1): 25-31.
[5] Obrink B. On the role of CEACAM1 in cancer[J]. Lung Cancer,2008,60(3): 309-312.
[6] Gaur S,Shively JE,Yen Y,et al. Altered splicing of CEACAM1 in breast cancer: identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms[J]. Mol Cancer,2008,7:46.
[7] Lucka L,Fernando M,Grunow D,et al. Identification of Lewis x structures of the cell adhesion molecule CEACAM1 from human granulocytes[J]. Glycobiology, 2005,15(1): 87-100.
[8] Hunter I,Sawa H,Edlund M,et al. Evidence for regulated dimerization of cell-cell adhesion molecule (C-CAM) in epithelial cells[J]. Biochem J,1996,320(Pt 3): 847-853.
[9] Ortenberg R,Sapir Y,Raz L, et al. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions[J]. Mol Cancer Ther, 2012,11(6): 1300-1310.
[10] Klaile E,Vorontsova O,Sigmundsson K,et al. The CEACAM1 N-terminal Ig domain mediates cis- and trans-binding and is essential for allosteric rearrangements of CEACAM1 microclusters[J]. J Cell Biol,2009,187(4): 553-567.
[11] Conners R,Hill DJ,Borodina E,et al. The Moraxella adhesin UspA1 binds to its human CEACAM1 receptor by a deformable trimeric coiled-coil[J]. EMBO J,2008,27(12) : 1779- 1789.
[12] Hirai A,Ohtsuka N,Ikeda T,et al. Role of mouse hepatitis virus (MHV) receptor murine CEACAM1 in the resistance of mice to MHV infection: studies of mice with chimeric mCEACAM1a and mCEACAM1b[J]. J Virol,2010,84(13): 6654-6666.
[13] Kuespert K,Roth A,Hauck CR. Neisseria meningitidis has two independent modes of recognizing its human receptor CEACAM1[J]. PLoS One,2011,6(1): e14609.
[14] Liu W, Wei W, Winer D,et al. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases[J]. Oncogene,2007,26(19): 2747-2758.
[15] Scheffrahn I,Singer BB,Sigmundsson K,et al. Control of density-dependent,cell state-specific signal transduction by the cell adhesion molecule CEACAM1,and its influence on cell cycle regulation[J]. Exp Cell Res, 2005,307(2): 427-435.
[16] Lee W. The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes[J]. Diagn Pathol,2011,6: 40.
[17] Huang S,Kaw M,Harris MT,et al. Decreased osteoclastogenesis and high bone mass in mice with impaired insulin clearance due to liver-specific inactivation to CEACAM1[J].Bone,2010,46(4): 1138-1145.
[18] Gerstel D,Wegwitz F,Jannasch K,et al. CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation[J]. Oncogene,2011,30(41): 4275-4288.
[19] Najjar SM,Ledford KJ,Abdallah SL,et al. Ceacam1 deletion causes vascular alterations in large vessels[J]. Am J Physiol Endocrinol Metab,2013,305(4): E519-E529.
[20] Killic N,Oliveira-Ferrer L,Neshat-Vahid S,et al. Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1[J]. Blood,2007,110(13): 4223-4233.
[21] Zhu J,Yang Y,Ma C,et al. CEACAM1 cytoplastic expression is closely related to tumor angiogenesis and poorer relapse-free survival after curative resection of hepatocellular carcinoma [J]. World J Surg,2011,35(10): 2259-2265.
[22] Zhou CJ,Liu B,Zhu KX,et al. The different expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) and possible roles in gastric carcinomas[J]. Pathol Res Pract, 2009,205(7): 483-489.
[23] Liu JN,Shang Guan YM,Qi YZ,et al. The evaluation of SOX9 expression and its relationship with carcinoembryonic antigen-related cell adhesion molecule 1 in gastric neoplastic and nonneoplastic lesions[J]. Ann Diagn Pathol, 2012,16(4): 235-244.
[24] Luo W,Wood CG,Earley K,et al. Suppression of tumorigenicity of breast cancer cells by an epithelial cell adhesion molecule (C-CAM1): the adhesion and growth suppression are mediated by different domains[J]. Oncogene,1997,14(14): 1697-1704.
[25] Kirshner J,Chen CJ,Liu P,et al. CEACAM1-4S,a cell-cell adhesion molecule,mediates apoptosis and reverts mammary carcinoma cells to a normal morphogenic phenotype in a 3D culture[J]. Proc Natl Acad Sci USA, 2003,100(2): 521-526.
[26] Samineni S,Glackin C,Shively JE. Role of CEACAM1,ECM,and mesenchymal stem cells in an orthotopic model of human breast cancer[J]. Int J Breast Cancer, 2011, 2011: 381080.
[27] Kleinerman DI,Troncoso P,Lin SH,et al. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor[J]. Cancer Res, 1995,55(6): 1215-1220.
[28] Ebrahimnejad A,Streichert T,Nollau P,et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells[J]. Am J Pathol, 2004,165(5): 1781-1787.
[29] Ieda J,Yokoyama S,Tamura K,et al. Re-expression of CEACAM1 long cytoplasmic domain isoform is associated with invasion and migration of colorectal cancer[J].Int J Cancer, 2011,129(6): 1351-1361.
[30] Horst AK,Ito WD,Dabelstein J,et al. Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo[J]. J Clin Invest, 2006,116(6):1596-1605.
[31] Ergün S,Kilik N,Ziegeler G,et al. CEA-related cell adhesion molecule 1: a potent angiogenic factor and a major effector of vascular endothelial growth factor[J]. Mol Cell,2000,5(2): 311-320.
[32] Tilki D,Irmak S,Oliveira-Ferrer L,et al. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer[J]. Oncogene, 2006,25(36):4965-4974.
[33] Oliveira-Ferrer L,Tilki D,Ziegeler G,et al. Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer[J].Cancer Res, 2004,64(24): 8932-8938.
[34] Fiori V,Magnani M,Cianfriglia M. The expression and modulation of CEACAM1 and tumor cell transformation[J]. Ann 1st Super Sanita,2012,48(2): 161-171.
[35] Simeone DM,Ji B, Banerjee M,et al. CEACAM1, a novel serum biomarker for pancreatic cancer[J]. Pancreas,2007,34(4): 436-443.
[36] Zhou MQ,Du Y,Liu YW,et al. Clinical and experimental studies regarding the expression and diagnostic value of carcinoembryonic antigen-related cell adhesion molecule 1 in non-small-cell lung cancer[J]. BMC Cancer,2013,13: 359.
[37] Markel G,Ortenberg R, Seidman R,et al. Systemic dysregulation of CEACAM1 in melanoma patients[J]. Cancer Immunol Immunother,2010,59(2): 215-230.
[38] Tilki D,Singer BB,Shariat SF,et al. CEACAM1: a novel urinary marker for bladder cancer detection[J]. Eur Urol, 2010,57(4): 648-654.
[39] Arabzadeh A,Chan C,Nouvion AL,et al. Host-related carcinoembryonic antigen cell adhesion molecule 1 promotes metastasis of colorectal cancer[J]. Oncogene,2013,32(7): 849-860.
[40] Beauchemin N,Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis[J].Cancer Metastasis Rev,2013,32(3-4): 643-671.
[41] Wang JL,Sun SZ,Qu X,et al. Clinicopathological significance of CEACAM1 gene expression in breast cancer[J]. Chin J Physiol,2011,54(5): 332-338.
[42] Kiriyama S,Yokoyama S,Ueno M,et al. CEACAM1 long cytoplasmic domain isoform is associated with invasion and recurrence of hepatocellular carcinoma[J]. Ann Surg Oncol, 2014. [Epub ahead of print]
[43] Sha QQ,Wei QZ,Zhu JK,et al. Loss of membranous carcinoembryonic antigen-related cell adhesion molecule 1 expression is related to decreased relapse-free survival of hepatocellular carcinoma following liver transplantation[J]. Chin Med J(Engl),2012,125(16): 2841-2845.
[44] 马莉,张蔚,许刚柱,等. 乙型肝炎病毒相关性肝癌患者癌组织中HBx和CEACAM1的表达及其意义[J].吉林大学学报(医学版),2012,38(40):779-783.
[45] Tsukada M,Wakai T,Matsuda Y,et al. Loss of carcinoembryonic antigen-related cell adhesion molecule 1 expression predicts metachronous pulmonary metastasis and poor survival in patients with hepatoblastoma[J]. J Pediatr Surg,2009,44(8): 1522-1528.
[46] 张小军,石爱平,许宁,等. 膀胱癌组织中癌胚抗原相关细胞黏附分子1蛋白表达的临床意义[J]. 中华泌尿外科杂志,2013,34(3): 235-236.
[47] Dango S,Sienel W,Schreiber M,et al. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer[J]. Lung Cancer,2008,60(3): 426-433.
[48] Thm I,Schult-Kronefeld O,Burkholder I,et al. Expression of CEACAM-1 in pulmonary adenocarcinomas and their metastases[J]. Anticancer Res,2009,29(1): 249-254.
[49] Sivan S,Suzan F,Rona O,et al. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients[J]. Clin Dev Immunol,2012,2012: 290536.
[50] Guo JQ,Yu WH,Wang HJ,et al. Different expression patterns of CEACAM1 and its impacts on angiogenesis in gastric nonneoplastic and neoplastic lesions[J]. Ann Surg Oncol, 2012,19(Suppl 3): S365-S374.

Carcinoembryonic antigen-related cell adhesion molecule 1 and tumor

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[2]	WANG Yangshuyi, YE WEI, LIN Zhihao, HUANG Yuenuo, FANG Tao, DONG Xiaoting. Construction and validation of a model for pyroptosis-related features in lung adenocarcinoma [J]. Laboratory Medicine, 2023, 38(9): 833-841.
[3]	PENG Wei, LI Yungai, XU Jing, LIU Hua, YANG Cuixia, SHEN Yunyue. Serum inflammatory factors combined with PSA and f-PSA in the auxiliary diagnosis of prostate cancer [J]. Laboratory Medicine, 2023, 38(9): 849-854.
[4]	ZHANG Han, LI Jun, LIU Xiaojiang, GUAN Yixiang. Role of serum albumin，interleukin-6 and ferritin combined determination in evaluating the functional prognosis of patients with spontaneous intracerebral hemorrhage [J]. Laboratory Medicine, 2023, 38(8): 713-718.
[5]	DING Xiaoyuan, DAI Jinsheng, JIAO Ronghong, MA Suli, ZHU Haifeng, WU Mengya, CHE Yanran, ZHANG Lei. Influence of obesity/overweight on inflammatory factors of Th1/Th2 and Th17/Treg in children with asthma attacks [J]. Laboratory Medicine, 2023, 38(8): 748-752.
[6]	ZHANG Na, NIU Weihua, SUN Yuanyuan, JIA Mei. CMV and EBV co-infection affecting patient prognosis after hematopoietic stem cell transplantation [J]. Laboratory Medicine, 2023, 38(8): 760-765.
[7]	GUO Jie, LI Haixia, LI Xiaoyun. Correlation of preoperative RPR in peripheral blood with the prognosis of endometrial carcinoma patients [J]. Laboratory Medicine, 2023, 38(7): 675-679.
[8]	WANG Tengfei, CHEN Shan, AN Hebing, ZHOU Lei. Expressions and roles of lncRNA CRNDE and miR-384 in peripheral blood of patients with acute leukemia [J]. Laboratory Medicine, 2023, 38(7): 686-691.
[9]	YIN Ya, PAN Yuan, ZHOU Hongwei, SHEN Wei. Application progress of BNP and NT-proBNP in neonates [J]. Laboratory Medicine, 2023, 38(6): 518-523.
[10]	ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418.
[11]	GAO Feng. Clinical application of novel tumor biomarkers：prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306.
[12]	SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351.
[13]	LIU Junshan, GUO Mingfa, SUN Jia, SHI Lihuan, LIU Wei, DUAN Yongtao. Significance of minimal residual disease dynamic monitoring in the prognosis of acute B-lymphoblastic leukemia children with positive and negative ETV6/RUNX1 fusion genes [J]. Laboratory Medicine, 2023, 38(3): 209-214.
[14]	CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256.
[15]	WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer [J]. Laboratory Medicine, 2023, 38(2): 190-195.